查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1600911

心臟衰竭藥物市場：按治療、類型、階段和最終用戶分類 - 全球預測 2025-2030

Heart Failure Therapeutics Market by Treatment (Medical Devices, Medicines, Surgery), Type (Diagnosis, Prognosis), Stage, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年心臟衰竭藥物市值為239.8億美元，預計2024年將達到261.6億美元，複合年成長率為10.46%，到2030年將達到481.3億美元。

心臟衰竭藥物市場包括多種旨在治療心臟衰竭的治療方案，心臟衰竭是一種心臟無法泵出足夠血液的慢性疾病，影響著全球整體數百萬人。該市場包括藥品、醫療設備以及基因療法等創新療法，旨在緩解症狀並提高患者的生活品質。心血管疾病的盛行率不斷上升、人口老化以及肥胖和糖尿病等與生活方式相關的危險因子的盛行率不斷上升，推動了對心臟衰竭藥物的需求。應用範圍從急診醫院到慢性門診醫療護理，最終用途擴展到醫院、診所、門診醫療中心和居家醫療。關鍵的成長要素包括診斷和治療方法的技術進步、正在進行的研究和臨床試驗以及強大的新藥研發管線。此外，政府措施和不斷上漲的醫療成本進一步推動了市場成長。新的商機在於個人化醫療和新型藥物輸送系統的開發，這些系統有望提高療效和患者依從性。製藥公司和研究機構之間的藥物發現和開發合作研究也是一個重要機會。然而，市場開拓面臨治療成本高、監管核准嚴格、藥物研發週期長等挑戰。此外，來自學名藥製造商的競爭可能會阻礙盈利。為了克服這些障礙，該行業應該專注於創新研究，例如識別生物標記、利用人工智慧進行藥物發現以及增強以患者為中心的護理模式。市場動態是動態的，競爭與合作並存，永續發展需要對研發進行策略性投資。推動政策改革，採用基於價值的醫療模式並簡化核准流程可以促進成長，為醫療保健相關人員提供進入這一不斷擴大的領域的機會。

主要市場統計
基準年[2023] 239.8億美元
預測年份 [2024] 261.6億美元
預測年份 [2030] 481.3億美元
複合年成長率（%） 10.46%

市場動態：揭示快速發展的心臟衰竭藥物市場的關鍵市場洞察

供需的動態交互作用正在改變心臟衰竭藥物市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 老年族群心血管疾病盛行率上升
    • 由於生活方式的改變，心臟衰竭和心律不整的敏感性增加
    • 心臟衰竭早期診斷和早期治療的可能性和偏好
  • 市場限制因素
    • 心臟衰竭治療的高成本和報銷問題
  • 市場機會
    • 心臟衰竭藥物的創新與開發
    • 政府的持續努力和私部門投資的增加
  • 市場挑戰
    • 對心臟衰竭病症管理的擔憂

波特五力：駕馭心臟衰竭藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對心臟衰竭藥物市場的影響

外部宏觀環境因素在塑造心臟衰竭藥物市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解心臟衰竭治療藥物市場的競爭狀況

對心臟衰竭藥物市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV心臟衰竭藥物市場定位矩陣供應商績效評估

FPNV定位矩陣是評估心臟衰竭藥物市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。四個象限清楚且準確地分類了供應商，幫助使用者辨識最能滿足其策略目標的合作夥伴和解決方案。

本報告提供了涵蓋關鍵重點領域的全面市場分析：

1. 市場滲透率：對當前市場環境的詳細回顧，包括行業主要企業的大量資料。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 老年族群心血管疾病盛行率上升
      • 生活方式的改變增加了心臟衰竭和心律不整的敏感性
      • 心臟衰竭早期診斷和治療的可用性和偏好
    • 抑制因素
      • 與心臟衰竭治療相關的高成本和報銷問題
    • 機會
      • 心臟衰竭藥物的創新與開發
      • 政府的持續努力和私部門投資的增加
    • 任務
      • 對心臟衰竭病症管理的擔憂
  • 市場區隔分析
    • 治療：消費者擴大轉向處方藥和個人化藥物來管理心臟健康
    • 類型：診斷工具和預後創新可以幫助您更好地管理心臟健康
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境
  • 客戶客製化

第6章心臟衰竭藥物市場：依治療分類

  • 醫療設備
    • 兩級正壓空氣裝置
    • 雙心室心律調節器
    • 持續正壓呼吸裝置
    • 心臟泵
    • 植入式心臟整流去顫器
    • 植入式左心室輔助裝置
  • 藥品
    • 血管收縮素II受體阻斷劑
    • 抗凝血物
    • 抗血小板藥
    • 血壓維持劑
    • 利尿劑
    • 硝酸鹽
    • 他汀類藥物
  • 外科手術
    • 心臟再同步
    • 冠狀動脈繞道手術手術
    • 冠狀動脈重組
    • 心臟移植
    • 心臟瓣膜置換術

第7章心臟衰竭藥物市場：依類型

  • 診斷
  • 預後

第8章心臟衰竭藥物市場：依階段

  • A階段
  • B階段
  • C階段
  • D階段

第9章心臟衰竭藥物市場：依最終用戶分類

  • 診所
  • 醫院
  • 醫學研究所

第10章北美和南美心臟衰竭藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太心臟衰竭藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲心臟衰竭藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭場景分析
    • FDA 快速核准治療心臟衰竭的基因治療藥物 AB-1002
    • 諾和諾德收購 Cardiol Pharmaceuticals，透過 RNA 標靶創新擴大心臟衰竭治療產品組合
    • 美國FDA核准Medtronic心臟病治療系統
    • 強生將斥資 4 億美元購買新型心臟植入，以減少中風
    • FDA核准使用帶有心臟力調節器的 MRI

公司名單

  • Cardiol Therapeutics Inc.
  • Johnson & Johnson Services, Inc.
  • Verve Therapeutics, Inc.
  • Impulse Dynamics
  • Abbott Laboratories
  • Jarvik Heart, Inc.
  • Berlin Heart GmbH
  • Dr. Reddy's Laboratories Limited
  • Amgen Inc.
  • Glenmark Pharmaceuticals Limited
  • Alembic Pharmaceuticals Limited
  • F. Hoffmann-La Roche Ltd.
  • Bristol-Myers Squibb Company
  • Medtronic PLC
  • Orion Corporation
  • Eli Lilly and Company
  • LivaNova, PLC
  • Cipla Limited
  • Novo Nordisk A/S
  • GlaxoSmithKline PLC
  • AstraZeneca PLC
  • Boston Scientific Corporation
  • Merck & Co., Inc.
  • Beckman Coulter, Inc.
  • Bayer AG
  • Osypka Medical GmbH
  • Biosensors International Group, Ltd.
  • Pfizer, Inc.
  • Biotronik SE & Co. KG
  • Novartis AG
Product Code: MRR-430D42AA0D2E

The Heart Failure Therapeutics Market was valued at USD 23.98 billion in 2023, expected to reach USD 26.16 billion in 2024, and is projected to grow at a CAGR of 10.46%, to USD 48.13 billion by 2030.

The heart failure therapeutics market encompasses a wide range of treatment options aimed at managing heart failure, a chronic condition marked by the heart's inability to pump sufficient blood, which affects millions globally. The scope of this market includes pharmaceuticals, medical devices, and other innovative treatments like gene therapy, designed to alleviate symptoms and improve patient quality of life. The necessity for heart failure therapeutics is driven by the increasing prevalence of cardiovascular diseases, an aging population, and the rising incidence of lifestyle-related risk factors such as obesity and diabetes. Applications range from acute hospital settings to chronic outpatient care, with end-use spread across hospitals, clinics, ambulatory care centers, and home healthcare. Key growth influencers include technological advancements in diagnostic and treatment modalities, ongoing research and clinical trials, and a strong pipeline of new drugs. Moreover, government initiatives and increased healthcare expenditure further augment market growth. Emerging opportunities lie in personalized medicine and the development of novel drug delivery systems, which promise improved efficacy and patient adherence. Collaborations between pharmaceutical companies and research institutions for drug discovery and development are also vital opportunities. However, market growth faces challenges such as high treatment costs, stringent regulatory approvals, and long drug development cycles. Additionally, competition from generic drug manufacturers can hamper profitability. To overcome these barriers, the industry should focus on innovative research in biomarker identification, utilizing artificial intelligence for drug discovery, and enhancing patient-centric care models. The heart failure therapeutics market is dynamic with a blend of competition and collaboration, necessitating strategic investment in R&D for sustained progress. Embracing value-based care models and pushing for policy reforms to streamline approval processes could vitalize growth, offering healthcare stakeholders a chance to tap into this expanding field.

KEY MARKET STATISTICS
Base Year [2023] USD 23.98 billion
Estimated Year [2024] USD 26.16 billion
Forecast Year [2030] USD 48.13 billion
CAGR (%) 10.46%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Heart Failure Therapeutics Market

The Heart Failure Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising Prevalence of Cardiovascular Diseases Among Geriatric Population
    • Growing Susceptibility to Heart Failure and Arrhythmia Owing to Changing Lifestyles
    • Availability and Preferences of Early Diagnosis and Management for Heart Failure
  • Market Restraints
    • High Cost and Reimbursement Issues Related to Heart Failure Treatment
  • Market Opportunities
    • Innovations and Development in the Heart Failure Therapeutics
    • Ongoing Government Initiatives and Increasing Investments by Private Sectors
  • Market Challenges
    • Concerns Related to Management of Heart Failure Condition

Porter's Five Forces: A Strategic Tool for Navigating the Heart Failure Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Heart Failure Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Heart Failure Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Heart Failure Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Heart Failure Therapeutics Market

A detailed market share analysis in the Heart Failure Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Heart Failure Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Heart Failure Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Heart Failure Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Cardiol Therapeutics Inc., Johnson & Johnson Services, Inc., Verve Therapeutics, Inc., Impulse Dynamics, Abbott Laboratories, Jarvik Heart, Inc., Berlin Heart GmbH, Dr. Reddy's Laboratories Limited, Amgen Inc., Glenmark Pharmaceuticals Limited, Alembic Pharmaceuticals Limited, F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Medtronic PLC, Orion Corporation, Eli Lilly and Company, LivaNova, PLC, Cipla Limited, Novo Nordisk A/S, GlaxoSmithKline PLC, AstraZeneca PLC, Boston Scientific Corporation, Merck & Co., Inc., Beckman Coulter, Inc., Bayer AG, Osypka Medical GmbH, Biosensors International Group, Ltd., Pfizer, Inc., Biotronik SE & Co. KG, and Novartis AG.

Market Segmentation & Coverage

This research report categorizes the Heart Failure Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment, market is studied across Medical Devices, Medicines, and Surgery. The Medical Devices is further studied across Bi-level positive air pressure device, Biventricular Pacemaker, Continuous Positive Air Pressure Device, Heart Pumps, Implantable Cardioverter-Defibrillators, and Implantable Left Ventricular Assist Device. The Medicines is further studied across Angiotensin II Receptor Blockers, Anticoagulant Medicines, Antiplatelet Medicines, Blood Pressure Maintaining Agents, Diuretics, Nitrates, and Statins. The Surgery is further studied across Cardiac Resynchronization, Coronary Artery Bypass Grafting, Coronary Revascularization, Heart Transplant, and Heart Valve Replacement.
  • Based on Type, market is studied across Diagnosis and Prognosis.
  • Based on Stage, market is studied across Stage A, Stage B, Stage C, and Stage D.
  • Based on End User, market is studied across Clinic, Hospital, and Medical Research Organization.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising Prevalence of Cardiovascular Diseases Among Geriatric Population
      • 5.1.1.2. Growing Susceptibility to Heart Failure and Arrhythmia Owing to Changing Lifestyles
      • 5.1.1.3. Availability and Preferences of Early Diagnosis and Management for Heart Failure
    • 5.1.2. Restraints
      • 5.1.2.1. High Cost and Reimbursement Issues Related to Heart Failure Treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Innovations and Development in the Heart Failure Therapeutics
      • 5.1.3.2. Ongoing Government Initiatives and Increasing Investments by Private Sectors
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns Related to Management of Heart Failure Condition
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment: Extensive consumers shift toward prescribed and personalized medicines for heart health management
    • 5.2.2. Type: Innovations in the diagnostic tools and prognosis helps in better managing the heart health condition
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental
  • 5.5. Client Customization

6. Heart Failure Therapeutics Market, by Treatment

  • 6.1. Introduction
  • 6.2. Medical Devices
    • 6.2.1. Bi-level positive air pressure device
    • 6.2.2. Biventricular Pacemaker
    • 6.2.3. Continuous Positive Air Pressure Device
    • 6.2.4. Heart Pumps
    • 6.2.5. Implantable Cardioverter-Defibrillators
    • 6.2.6. Implantable Left Ventricular Assist Device
  • 6.3. Medicines
    • 6.3.1. Angiotensin II Receptor Blockers
    • 6.3.2. Anticoagulant Medicines
    • 6.3.3. Antiplatelet Medicines
    • 6.3.4. Blood Pressure Maintaining Agents
    • 6.3.5. Diuretics
    • 6.3.6. Nitrates
    • 6.3.7. Statins
  • 6.4. Surgery
    • 6.4.1. Cardiac Resynchronization
    • 6.4.2. Coronary Artery Bypass Grafting
    • 6.4.3. Coronary Revascularization
    • 6.4.4. Heart Transplant
    • 6.4.5. Heart Valve Replacement

7. Heart Failure Therapeutics Market, by Type

  • 7.1. Introduction
  • 7.2. Diagnosis
  • 7.3. Prognosis

8. Heart Failure Therapeutics Market, by Stage

  • 8.1. Introduction
  • 8.2. Stage A
  • 8.3. Stage B
  • 8.4. Stage C
  • 8.5. Stage D

9. Heart Failure Therapeutics Market, by End User

  • 9.1. Introduction
  • 9.2. Clinic
  • 9.3. Hospital
  • 9.4. Medical Research Organization

10. Americas Heart Failure Therapeutics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Heart Failure Therapeutics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Heart Failure Therapeutics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. FDA Grants Fast Track Status to AB-1002 Gene Therapy for Heart Failure
    • 13.3.2. Novo Nordisk to Acquire Cardior Pharmaceuticals, Expanding Heart Failure Therapeutic Portfolio with RNA-Targeted Innovations
    • 13.3.3. US FDA approves Medtronic's system for heart condition
    • 13.3.4. J&J drops USD 400 million to acquire new type of stroke-reducing heart implant
    • 13.3.5. FDA Clears MRI Use with Cardiac Contractility Modulation Device

Companies Mentioned

  • 1. Cardiol Therapeutics Inc.
  • 2. Johnson & Johnson Services, Inc.
  • 3. Verve Therapeutics, Inc.
  • 4. Impulse Dynamics
  • 5. Abbott Laboratories
  • 6. Jarvik Heart, Inc.
  • 7. Berlin Heart GmbH
  • 8. Dr. Reddy's Laboratories Limited
  • 9. Amgen Inc.
  • 10. Glenmark Pharmaceuticals Limited
  • 11. Alembic Pharmaceuticals Limited
  • 12. F. Hoffmann-La Roche Ltd.
  • 13. Bristol-Myers Squibb Company
  • 14. Medtronic PLC
  • 15. Orion Corporation
  • 16. Eli Lilly and Company
  • 17. LivaNova, PLC
  • 18. Cipla Limited
  • 19. Novo Nordisk A/S
  • 20. GlaxoSmithKline PLC
  • 21. AstraZeneca PLC
  • 22. Boston Scientific Corporation
  • 23. Merck & Co., Inc.
  • 24. Beckman Coulter, Inc.
  • 25. Bayer AG
  • 26. Osypka Medical GmbH
  • 27. Biosensors International Group, Ltd.
  • 28. Pfizer, Inc.
  • 29. Biotronik SE & Co. KG
  • 30. Novartis AG

LIST OF FIGURES

  • FIGURE 1. HEART FAILURE THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. HEART FAILURE THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. HEART FAILURE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. HEART FAILURE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. HEART FAILURE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. HEART FAILURE THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY BI-LEVEL POSITIVE AIR PRESSURE DEVICE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY BIVENTRICULAR PACEMAKER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CONTINUOUS POSITIVE AIR PRESSURE DEVICE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART PUMPS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY IMPLANTABLE LEFT VENTRICULAR ASSIST DEVICE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ANGIOTENSIN II RECEPTOR BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANT MEDICINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET MEDICINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY BLOOD PRESSURE MAINTAINING AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DIURETICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY NITRATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY STATINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CARDIAC RESYNCHRONIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CORONARY REVASCULARIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART TRANSPLANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART VALVE REPLACEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY PROGNOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE A, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE B, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE C, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE D, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CLINIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL RESEARCH ORGANIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 66. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 67. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 68. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 69. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 70. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 73. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 74. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 75. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 76. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 77. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 79. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 80. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 81. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 82. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 83. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 84. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 86. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 87. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 96. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 97. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 98. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 99. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 100. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 102. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 103. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 104. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 105. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 106. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 107. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 109. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 110. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 111. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 112. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 113. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 114. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 116. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 117. INDONESIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 118. INDONESIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 119. INDONESIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 120. INDONESIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 121. INDONESIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. INDONESIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 123. INDONESIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 124. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 125. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 126. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 127. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 128. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 130. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 131. MALAYSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 132. MALAYSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 133. MALAYSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 134. MALAYSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 135. MALAYSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. MALAYSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 137. MALAYSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 138. PHILIPPINES HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 139. PHILIPPINES HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 140. PHILIPPINES HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 141. PHILIPPINES HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 142. PHILIPPINES HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. PHILIPPINES HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 144. PHILIPPINES HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 145. SINGAPORE HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 146. SINGAPORE HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 147. SINGAPORE HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 148. SINGAPORE HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 149. SINGAPORE HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. SINGAPORE HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 151. SINGAPORE HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 152. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 153. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 154. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 155. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 156. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 158. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 159. TAIWAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 160. TAIWAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 161. TAIWAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 162. TAIWAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 163. TAIWAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. TAIWAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 165. TAIWAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 166. THAILAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 167. THAILAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 168. THAILAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 169. THAILAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 170. THAILAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. THAILAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 172. THAILAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 173. VIETNAM HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 174. VIETNAM HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 175. VIETNAM HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 176. VIETNAM HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 177. VIETNAM HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. VIETNAM HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 179. VIETNAM HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 188. DENMARK HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 189. DENMARK HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 190. DENMARK HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 191. DENMARK HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 192. DENMARK HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. DENMARK HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 194. DENMARK HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 195. EGYPT HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 196. EGYPT HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 197. EGYPT HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 198. EGYPT HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 199. EGYPT HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. EGYPT HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 201. EGYPT HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 202. FINLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 203. FINLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 204. FINLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 205. FINLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 206. FINLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. FINLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 208. FINLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 209. FRANCE HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 210. FRANCE HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 211. FRANCE HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 212. FRANCE HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 213. FRANCE HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. FRANCE HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 215. FRANCE HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 216. GERMANY HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 217. GERMANY HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 218. GERMANY HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 219. GERMANY HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 220. GERMANY HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. GERMANY HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 222. GERMANY HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 223. ISRAEL HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 224. ISRAEL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 225. ISRAEL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 226. ISRAEL HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 227. ISRAEL HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. ISRAEL HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 229. ISRAEL HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 230. ITALY HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 231. ITALY HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 232. ITALY HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 233. ITALY HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 234. ITALY HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 235. ITALY HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 236. ITALY HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 237. NETHERLANDS HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 238. NETHERLANDS HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 239. NETHERLANDS HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 240. NETHERLANDS HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 241. NETHERLANDS HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 242. NETHERLANDS HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 243. NETHERLANDS HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 244. NIGERIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 245. NIGERIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 246. NIGERIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 247. NIGERIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 248. NIGERIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 249. NIGERIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 250. NIGERIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 251. NORWAY HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 252. NORWAY HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 253. NORWAY HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 254. NORWAY HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 255. NORWAY HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 256. NORWAY HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 257. NORWAY HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 258. POLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 259. POLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 260. POLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 261. POLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 262. POLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 263. POLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 264. POLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 265. QATAR HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 266. QATAR HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 267. QATAR HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 268. QATAR HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 269. QATAR HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 270. QATAR HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 271. QATAR HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 272. RUSSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 273. RUSSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 274. RUSSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 275. RUSSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 276. RUSSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 277. RUSSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 278. RUSSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 279. SAUDI ARABIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 280. SAUDI ARABIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 281. SAUDI ARABIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 282. SAUDI ARABIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 283. SAUDI ARABIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 284. SAUDI ARABIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 285. SAUDI ARABIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 286. SOUTH AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 287. SOUTH AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 288. SOUTH AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 289. SOUTH AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 290. SOUTH AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 291. SOUTH AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 292. SOUTH AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 293. SPAIN HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 294. SPAIN HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 295. SPAIN HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 296. SPAIN HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 297. SPAIN HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 298. SPAIN HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 299. SPAIN HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 300. SWEDEN HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 301. SWEDEN HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 302. SWEDEN HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 303. SWEDEN HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 304. SWEDEN HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 305. SWEDEN HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 306. SWEDEN HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 307. SWITZERLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 308. SWITZERLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 309. SWITZERLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 310. SWITZERLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 311. SWITZERLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 312. SWITZERLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 313. SWITZERLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 314. TURKEY HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 315. TURKEY HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 316. TURKEY HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 317. TURKEY HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 318. TURKEY HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 319. TURKEY HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 320. TURKEY HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 321. UNITED ARAB EMIRATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 322. UNITED ARAB EMIRATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 323. UNITED ARAB EMIRATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 324. UNITED ARAB EMIRATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 325. UNITED ARAB EMIRATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 326. UNITED ARAB EMIRATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 327. UNITED ARAB EMIRATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 328. UNITED KINGDOM HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 329. UNITED KINGDOM HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 330. UNITED KINGDOM HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 331. UNITED KINGDOM HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 332. UNITED KINGDOM HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)

TAB